Navigation Links
Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule
Date:6/5/2009

WELLESLEY HILLS, Ma., June 5 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that he has received a statement from Ludwig Institute of Cancer Research Ltd., Brussels Branch. The statement is quoted in its entirety below.

"Prospect Therapeutics' lead product candidate, GCS-100, is a carbohydrate molecule which inhibits the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers. Prospect reported that GCS-100 could induce apoptosis of cancer cells and that clinical trial results indicated that reduction in leukemic cell number could be obtained without severe side effects.

"In addition to its direct effect on tumor cells, GCS-100 could have an important role on the immune system of cancer patients. A team at the Brussels Branch of the Ludwig Institute has found that human tumors contain a large number of T lymphocytes which are directed against specific antigens of the tumor cells, but that these lymphocytes are in a state of paralysis. An important component of this paralysis appears to be the trapping of T cell receptors in a galectin-3 lattice on the cell surface. The function of these T lymphocytes could readily be restored in vitro by addition of Galectin-binding sugar molecules, including GCS-100. This suggests that GCS-100 could be used in combination with anti-tumoral vaccination to induce the rejection of cancer cells in patients."

The intellectual property, regulatory dossier, fixed assets and clinical inventory of Prospect will be sold at auction on Monday, June 29, 2009 at 12:00 noon ET.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Prospect Therapeutics, Inc.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net or visit the website at www.finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
2. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
3. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
4. LifeNet Health Establishes The Skin & Wound Allograft Institute
5. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
6. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
7. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
8. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
9. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
10. Bullying Prevention Institute Designed to Empower Change in Schools
11. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Overland Park, KS (PRWEB) , ... January 18, ... ... family managed firm offering asset protection and financial planning services to families and ... for a charity event aimed at supporting children with developmental disabilities. , The ...
(Date:1/18/2017)... Alexandria, VA (PRWEB) , ... January 18, 2017 , ... ... services in family, cosmetic and implants dentistry. His modern dental practice has two convenient ... Qureshi as a 2017 Top Rated Dentist for the Alexandria area. This ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. ... website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President ... the field of biosimilars through thought leader interaction in, live video and interactive ...
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
(Date:1/18/2017)... ... 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse to ... a reset. The U.S. Apple Association agrees and recommends starting each day with ... contribute to heart disease. , The U.S. Apple Association – which represents apple growers ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Adaptive Sound Technologies, Inc. ... a new partnership with Hyatt Place Nashville/Downtown to deliver ... ASTI LectroFan sleep therapy machines in over two hundred ... the most important parts of having a great stay ... manager of Hyatt Place Nashville/Downtown. "We,re pleased to be ...
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
Breaking Medicine Technology: